Cargando…

Long-term Survival of Locally Advanced Stage III Non-small Cell Lung Cancer Patients Treated with Chemoradiotherapy and Perspectives for The Treatment with Immunotherapy

BACKGROUND: Standard treatment for patients with inoperable locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT). Five-year overall survival rates range between 15 and 25%, while long term survival data are rarely reported. PATIENTS AND METHODS: A total of 102 p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vrankar, Martina, Stanic, Karmen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sciendo 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137367/ https://www.ncbi.nlm.nih.gov/pubmed/30210037 http://dx.doi.org/10.2478/raon-2018-0009

Ejemplares similares

Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy
por: Vrankar, Martina, et al.
Publicado: (2020)

Clinical Outcomes in Stage III Non-small Cell Lung Cancer Patients Treated with Durvalumab After Sequential Or Concurrent Platinum-based Chemoradiotherapy – Single Institute Experience
por: Vrankar, Martina, et al.
Publicado: (2021)

Consolidation Radiotherapy for Patients with Extended Disease Small Cell Lung Cancer in a Single Tertiary Institution: Impact of Dose and Perspectives in the Era of Immunotherapy
por: Stanic, Karmen, et al.
Publicado: (2020)

Local control and survival after stereotactic body radiation therapy of early-stage lung cancer patients in Slovenia
por: Stanic, Karmen, et al.
Publicado: (2023)

Incorporation of EGFR Mutation Status into M Descriptor of New TNM Classification Influences Survival Curves in Non-small Cell Lung Cancer Patients
por: Stanic, Karmen, et al.
Publicado: (2019)

Treatment Patterns and Real-world Evidence for Stage III Non-small Cell Lung Cancer in Central and Eastern Europe
por: Zemanova, Milada, et al.
Publicado: (2020)

Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations
por: Zwitter, Matjaz, et al.
Publicado: (2014)

Immune RECIST Criteria and Symptomatic Pseudoprogression in Non-small Cell Lung Cancer Patients Treated with Immunotherapy
por: Vrankar, Martina, et al.
Publicado: (2018)

Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
por: Zwitter, Matjaz, et al.
Publicado: (2016)

Advances in immunotherapy for stage III non-small cell lung cancer: moving immune checkpoint inhibitors to the front lines concurrently with chemoradiotherapy?
por: Hida, Toyoaki, et al.
Publicado: (2020)

Postoperative Adjuvant Chemoradiotherapy on the Survival of Stage III Gastric Cancer
por: Li, Chao, et al.
Publicado: (2022)

Consolidation chwemotherapy after concurrent chemoradiotherapy vs. chemoradiotherapy alone for locally advanced unresectable stage III non-small-cell lung cancer: A meta-analysis
por: Chang, Xiu-Jun, et al.
Publicado: (2016)

The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy
por: Koo, Tae Ryool, et al.
Publicado: (2014)

Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy
por: Guan, Xiaoxiang, et al.
Publicado: (2010)

Retracted: Postoperative Adjuvant Chemoradiotherapy on the Survival of Stage III Gastric Cancer
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
por: Sher, David J.
Publicado: (2017)

Recent Advances in Combination of Immunotherapy and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
por: Wang, Ruixi, et al.
Publicado: (2022)

Development and validation of a prediction model using molecular marker for long‐term survival in unresectable stage III non‐small cell lung cancer treated with chemoradiotherapy
por: Yang, Yufan, et al.
Publicado: (2021)

MRI Radiomics for Predicting Survival in Patients with Locally Advanced Hypopharyngeal Cancer Treated with Concurrent Chemoradiotherapy
por: Siow, Tiing Yee, et al.
Publicado: (2022)

Early recurrence factors in patients with stage III non‐small cell lung cancer treated with concurrent chemoradiotherapy
por: Takahara, Yutaka, et al.
Publicado: (2022)

Influence of oral glutamine supplementation on survival outcomes of patients treated with concurrent chemoradiotherapy for locally advanced non-small cell lung cancer
por: Topkan, Erkan, et al.
Publicado: (2012)

Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
por: Bergamino, Milana, et al.
Publicado: (2019)

Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana
por: Stanic, Karmen, et al.
Publicado: (2010)

Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer
por: Kang, Ki Mun, et al.
Publicado: (2012)

Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer
por: Conibear, John
Publicado: (2020)

Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review)
por: Łazar-Poniatowska, Małgorzata, et al.
Publicado: (2021)

Induction gemcitabine in standard dose or prolonged low-dose with cisplatin followed by concurrent radiochemotherapy in locally advanced non-small cell lung cancer: a randomized phase II clinical trial
por: Vrankar, Martina, et al.
Publicado: (2014)

Increased lymph node yield indicates improved survival in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
por: Wang, Yaqi, et al.
Publicado: (2019)

Pretreatment Masseter Muscle Volume Predicts Survival in Locally Advanced Nasopharyngeal Carcinoma Patients Treated with Concurrent Chemoradiotherapy
por: Pehlivan, Umur Anil, et al.
Publicado: (2023)

Surgical issues in locally advanced rectal cancer treated by preoperative chemoradiotherapy
por: Lim, Seok-Byung, et al.
Publicado: (2013)

Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy
por: Honma, Yoshitaka, et al.
Publicado: (2019)

Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
por: Sen, Fatma, et al.
Publicado: (2016)

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
por: Spigel, David R., et al.
Publicado: (2022)

Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer
por: Kishi, Noriko, et al.
Publicado: (2022)

Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy
por: Yu, Xiaojuan, et al.
Publicado: (2015)

Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer in comparison with chemoradiotherapy alone
por: Abe, Takanori, et al.
Publicado: (2020)

Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy
por: Dang, Jun, et al.
Publicado: (2014)

Prognostic and Predictive Biomarkers in Patients with Locally Advanced Rectal Cancer (LARC) Treated with Preoperative Chemoradiotherapy
por: Martín-Carnicero, Alfonso, et al.
Publicado: (2022)

High Pretreatment Platelet-to-Albumin Ratio Predicts Poor Survival Results in Locally Advanced Nasopharyngeal Cancers Treated with Chemoradiotherapy
por: Haksoyler, Veysel, et al.
Publicado: (2021)

Survival outcomes analysis according to mismatch repair status in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy
por: Chen, Lin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m7hbqkhbhqb85dpr726a1gqdfd